Editorial: von Willebrand factor and CRP levels may predict survival in liver cirrhosis—Authors’ reply

rocyte ischaemia, intestinal barrier dysfunction and bacterial translocation. Indeed a relationship between VWF and the pro-coagulant state (factor VIII/protein C ratio, P = 0.507; P < 0.001) is also present. This vicious circle may perpetuate the chronic systemic inflammation, independently from portal hypertension (Figure 1). Furthermore, as in previous reports, the authors find that VWF levels are associated with important clinical events in cirrhosis (variceal bleeding, paracentesis and bacterial infections) but, interestingly, this relationship is independent from patients’ HVPG. Finally, Mandorfer and coworkers develop a score including VWF > 367% and Reactive C Protein (CRP) > 6.5 mg/dL which identifies three groups of patients with different mortality. Patients in the intermediate or high risk groups show +80% and +259% increase in the mortality risk, respectively. This result suggests that endothelial dysfunction and systemic inflammation, as assessed by high levels of VWF and CRP, have a strong detrimental prognostic influence per se. This prognostic score obviously needs to be validated prospectively in an independent series of patients. If confirmed it could become a welcome noninvasive marker for prognosis in patients with cirrhosis.

[1]  M. Merli,et al.  Editorial: von Willebrand factor and CRP levels may predict survival in liver cirrhosis , 2018, Alimentary pharmacology & therapeutics.

[2]  D. Bauer,et al.  Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity , 2018, Alimentary pharmacology & therapeutics.

[3]  C. Crescioli,et al.  Gut-derived endotoxin stimulates factor VIII secretion from endothelial cells. Implications for hypercoagulability in cirrhosis. , 2017, Journal of hepatology.

[4]  M. Rudler,et al.  A randomized trial of 6-month norfloxacin therapy in patients with Child-Pugh class C cirrhosis , 2017 .

[5]  D. Christodoulou,et al.  von Willebrand factor and procoagulant imbalance predict outcome in patients with cirrhosis and thrombocytopenia. , 2016, Journal of hepatology.

[6]  J. Bosch,et al.  Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis. , 2016, Gastroenterology.

[7]  R. Moreau,et al.  Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis. , 2015, Journal of hepatology.

[8]  M. Kiehntopf,et al.  Imbalance of von Willebrand factor and its cleaving protease ADAMTS13 during systemic inflammation superimposed on advanced cirrhosis , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[9]  F. Lammert,et al.  Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. , 2013, Journal of hepatology.

[10]  D. Valla,et al.  Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. , 2012, Gastroenterology.

[11]  J. Bosch,et al.  Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension , 2011, Gut.

[12]  L. Blendis,et al.  Hepatic and portal vein thrombosis in cirrhosis: Possible role in development of parenchymal extinction and portal hypertension , 1995, Hepatology.